NICE Ltd.

3 Things You Need to Know Before Buying Tesla

This is an extremely ambitious company whose early shareholders have profited nicely.

Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study

RHHBY's enicepatide cut HbA1c and body weight in a phase II study, strengthening its obesity ambitions as it advances the drug into phase III.

Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trial

Roche (USOTC:RHHBY) has reported positive results from a mid-stage clinical trial of its experimental obesity treatment enicepatide, with patients who have type 2 diabetes achieving average weight loss of 15. 5% alongside improvements in blood sugar control.

Should You Buy SpaceX Stock Before Its Next Earnings Report?

SpaceX stock has rebounded nicely since its prior sell-off, but can the momentum last until its next earnings report?

Speak Up for the World's Children: Urge Congress to Release Approved UNICEF Funding

Non-Tech Stocks Can Still Deliver Huge Gains

Perhaps to the surprise of some, a few non-technology companies have seen wildly strong performances YTD, with their lower-beta nature providing a nice shield against volatility.

EOD: Distribution Growth Is Nice But Sector Allocation Might Not Be Ideal

The Allspring Global Dividend Opportunity Fund offers a 9.31% yield, variable distribution, portfolio risks, and 9.12% NAV discount. Click to read more on EOD.

AbbVie Exec Says Apogee Fits 'Very Nicely' With Its Business Development Approach; Says Existing Portfolio Provides 'Clear Line Of Sight' To Very Strong Growth Well Into Next Decade

 - conference call

A foldable iPhone is nice, but Apple still needs to improve its AI user experience

Apple (AAPL) is expected to unveil its foldable iPhone on Wednesday at its "Surprise and Shine" event. This will be CEO John Ternus's first product launch as chief executive. Sherwood News head of markets Luke Kawa and Investopedia editor in chief Caleb Silver chat with Morning Brief host Julie Hyman about their expectations for the launch.

Lilly Launches Foundayo in the UK as NICE Review Continues

Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch […]